DGX Quest Diagnostics
NYSE · SEC CIK 1022079 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $37.31M 23 sales by 8 insiders
- Filings on record
- 341 since 2021-07-06, latest 2026-09-03 17:05
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Davis J. E. | CEO, Pres, Dir | — | $17.08M |
| Doherty Catherine T. | EVP, Regional Businesses | — | $6.96M |
| PREVOZNIK MICHAEL E | SVP, GC | — | $6.69M |
| KUPPUSAMY KARTHIK | SVP, Clinical Solutions | — | $2.17M |
| Plewman Patrick | SVP for Diagnostic Services | — | $2.03M |
| DELANEY MARK E | SVP, Chief Commercial Off | — | $1.86M |
| PFEIFFER GARY M | Dir | — | $270.3K |
| Gregg Vicky B | Dir | — | $239.7K |
| Lassiter Wright III | Dir | — | — |
| Deppe Michael J | SVP, CAO, Corp. Ctrl | — | — |
Transactions 434
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-03-09 | 2022-03-07 | DGX | EGLINTON MANNER CARRIE | SVP, Advanced Diagnostics | F - Tax | $130.09 | -7,947 | 48.4K | -14% | -$1.03M | |
| 2022-03-09 | 2022-03-07 | DGX | Davis J. E. | EVP-Gen. Diagnostics, CEO Elect | A - Grant | $130.09 | +19.9K | 77.1K | +35% | +$2.58M | |
| 2022-03-09 | 2022-03-07 | DGX | Davis J. E. | EVP-Gen. Diagnostics, CEO Elect | F - Tax | $130.09 | -10.3K | 66.8K | -13% | -$1.34M | |
| 2022-03-09 | 2022-03-08 | DGX | Doherty Catherine T. | SVP, Group Exec. Clin. Fran | S - Sale | $135.21 | -7,032 | 67.7K | -9% | -$950.8K | |
| 2022-03-09 | 2022-03-07 | DGX | Doherty Catherine T. | SVP, Group Exec. Clin. Fran | A - Grant | $130.09 | +13.4K | 81.1K | +20% | +$1.74M | |
| 2022-03-09 | 2022-03-07 | DGX | Doherty Catherine T. | SVP, Group Exec. Clin. Fran | F - Tax | $130.09 | -6,360 | 74.8K | -8% | -$827.4K | |
| M | 2022-03-09 | 2022-03-07 | DGX | DEPPE MICHAEL J | VP, CAO, Corp. Ctrl | F - Tax | $130.09 | -914 | 32.0K | -3% | -$118.9K |
| M | 2022-03-09 | 2022-03-07 | DGX | DEPPE MICHAEL J | VP, CAO, Corp. Ctrl | A - Grant | $130.09 | +2,516 | 32.1K | +9% | +$327.3K |
| 2022-03-02 | 2022-02-28 | DGX | PREVOZNIK MICHAEL E | SVP, GC | S - Sale | $130.00 | -661 | 39.2K | -2% | -$85.9K | |
| D | 2022-02-28 | 2022-02-24 | DGX | GUINAN MARK | EVP, CFO | A - Grant | $0.00 | +2,251 | 88.7K | +3% | $0 |
| D | 2022-02-28 | 2022-02-24 | DGX | PREVOZNIK MICHAEL E | SVP, GC | A - Grant | $0.00 | +2,741 | 39.9K | +7% | $0 |
| D | 2022-02-28 | 2022-02-24 | DGX | PREVOZNIK MICHAEL E | SVP, GC | S - Sale | $126.26 | -1,669 | 37.1K | -4% | -$210.7K |
| D | 2022-02-28 | 2022-02-24 | DGX | RUSCKOWSKI STEPHEN H | COB, CEO, Pres, Dir | A - Grant | $0.00 | +22.5K | 297.2K | +8% | $0 |
| D | 2022-02-28 | 2022-02-24 | DGX | Davis J. E. | EVP-Gen. Diagnostics, CEO Elect | A - Grant | $0.00 | +9,787 | 57.3K | +21% | $0 |
| D | 2022-02-28 | 2022-02-24 | DGX | Doherty Catherine T. | SVP, Group Exec. Clin. Fran | A - Grant | $0.00 | +3,328 | 67.7K | +5% | $0 |
| D | 2022-02-28 | 2022-02-24 | DGX | Doherty Catherine T. | SVP, Group Exec. Clin. Fran | S - Sale | $126.26 | -2,750 | 64.4K | -4% | -$347.2K |
| DM | 2022-02-28 | 2022-02-24 | DGX | EGLINTON MANNER CARRIE | SVP, Advanced Diagnostics | A - Grant | $0.00 | +11.7K | 40.2K | +41% | $0 |
| DM | 2022-02-28 | 2022-02-24 | DGX | DEPPE MICHAEL J | VP, CAO, Corp. Ctrl | A - Grant | $0.00 | +3,681 | 27.3K | +16% | $0 |
| M | 2022-02-25 | 2022-02-23 | DGX | RUSCKOWSKI STEPHEN H | COB, CEO, Pres, Dir | F - Tax | $130.12 | -9,718 | 277.0K | -3% | -$1.26M |
| M | 2022-02-25 | 2022-02-23 | DGX | Davis J. E. | EVP-Gen. Diagnostics, CEO Elect | F - Tax | $130.13 | -2,436 | 48.2K | -5% | -$317.0K |
| M | 2022-02-25 | 2022-02-23 | DGX | PREVOZNIK MICHAEL E | SVP, GC | F - Tax | $130.13 | -1,339 | 38.8K | -3% | -$174.2K |
| M | 2022-02-25 | 2022-02-23 | DGX | DEPPE MICHAEL J | VP, CAO, Corp. Ctrl | F - Tax | $130.13 | -313 | 26.6K | -1% | -$40.7K |
| M | 2022-02-25 | 2022-02-23 | DGX | GUINAN MARK | EVP, CFO | F - Tax | $130.13 | -2,367 | 86.4K | -3% | -$308.0K |
| M | 2022-02-25 | 2022-02-23 | DGX | Doherty Catherine T. | SVP, Group Exec. Clin. Fran | F - Tax | $130.13 | -1,574 | 67.6K | -2% | -$204.8K |
| M | 2022-02-25 | 2022-02-23 | DGX | EGLINTON MANNER CARRIE | SVP, Advanced Diagnostics | F - Tax | $130.13 | -1,977 | 28.9K | -6% | -$257.3K |
| D | 2021-12-01 | 2021-11-29 | DGX | Doherty Catherine T. | SVP, Group Exec. Clin. Fran | M - OptEx | $95.80 | +37.6K | 106.3K | +55% | +$3.60M |
| DM | 2021-12-01 | 2021-11-29 | DGX | Doherty Catherine T. | SVP, Group Exec. Clin. Fran | S - Sale+OE | $156.81 | -37.6K | 83.3K | -31% | -$5.89M |
| 2021-08-17 | 2021-08-16 | DGX | Doi Tracey | Dir | A - Grant | $0.00 | +905 | 905 | New | $0 | |
| DM | 2021-07-30 | 2021-07-28+ | DGX | RUSCKOWSKI STEPHEN H | COB, CEO, Pres, Dir | M - OptEx | $95.80 | +149.2K | 424.2K | +54% | +$14.30M |
| DM | 2021-07-30 | 2021-07-28+ | DGX | RUSCKOWSKI STEPHEN H | COB, CEO, Pres, Dir | S - Sale+OE | $140.19 | -149.2K | 284.4K | -34% | -$20.92M |
| DM | 2021-07-28 | 2021-07-27 | DGX | WILENSKY GAIL R | Dir | M - OptEx | $59.40 | +12.2K | 24.0K | +104% | +$726.0K |
| DM | 2021-07-28 | 2021-07-27 | DGX | WILENSKY GAIL R | Dir | S - Sale+OE | $139.29 | -12.2K | 17.8K | -41% | -$1.70M |
| DM | 2021-07-28 | 2021-07-26+ | DGX | RUSCKOWSKI STEPHEN H | COB, CEO, Pres, Dir | M - OptEx | $95.80 | +38.6K | 317.2K | +14% | +$3.70M |
| DM | 2021-07-28 | 2021-07-26+ | DGX | RUSCKOWSKI STEPHEN H | COB, CEO, Pres, Dir | S - Sale+OE | $140.01 | -38.6K | 284.4K | -12% | -$5.40M |
Purchase Sale Sale after option exercise All abbreviations